Evidence map›Paper›PMID 37217466›Full record

ArticleNature communications2023

Molecular basis of differential HLA class I-restricted T cell recognition of a highly networked HIV peptide.

Xiaolong Li, Nishant Kumar Singh, David R Collins, Robert Ng, Angela Zhang, Pedro A Lamothe-Molina, Peter Shahinian, Shutong Xu, Kemin Tan, Alicja Piechocka-Trocha and 11 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor selectivity.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 2 countries.

Xiaolong LiSchool of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China. xiaolong@crystal.harvard.edu.ORCID 0000-0001-6549-4089
Nishant Kumar SinghRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
David R CollinsRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0001-7903-346X
Robert NgDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Angela ZhangRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Pedro A Lamothe-MolinaRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0001-9262-2920
Peter ShahinianRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0003-0435-2583
Shutong XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.ORCID 0000-0002-9894-1735
Kemin TanStructural Biology Center, X-ray Science Division, Advanced Photon Source, Argonne National Laboratory, Lemont, IL, 60439, USA.ORCID 0000-0002-4003-7903
Alicja Piechocka-TrochaRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Jonathan M UrbachRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0003-0597-2848
Jeffrey K WeberIBM Thomas J. Watson Research Center, Computational Biology Center, Yorktown Heights, NY, 10598, USA.
Gaurav D GaihaRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Overbeck Christian Takou MbahRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
Tien HuynhIBM Thomas J. Watson Research Center, Computational Biology Center, Yorktown Heights, NY, 10598, USA.
Sophia CheeverRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.
James ChenRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0001-6039-613X
Michael BirnbaumRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0002-2281-3518
Ruhong ZhouIBM Thomas J. Watson Research Center, Computational Biology Center, Yorktown Heights, NY, 10598, USA.ORCID 0000-0001-8624-5591
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, 02139, USA. bwalker@mgh.harvard.edu.ORCID 0000-0001-6122-9245
Jia-Huai WangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. jwang@crystal.harvard.edu.ORCID 0000-0003-3478-829X
Ragon Institute of MGH, MIT and Harvard · USHarvard University · USHoward Hughes Medical Institute · USIBM Research - Thomas J. Watson Research Center · USArgonne National Laboratory · USUniversity of Science and Technology of China · CN

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Structures of Alpha 4 Integrins, Ligands and AntagonistsP01HL103526 · NHLBI · IMMUNE DISEASE INSTITUTE, INC. · PI SPRINGER, TIMOTHY A · 2011 to 2015
$11.1M
Understanding and Reversing T Cell Dysfunction to Control and Eliminate Persistent HIV ReservoirsR01AI149704 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2020 to 2024
$2.1M
Bill & Melinda Gates Foundation INV-002703Howard Hughes Medical InstituteNHLBI NIH HHS P01 HL103526NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI149704NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Cytotoxic-T-lymphocyte (CTL) mediated control of HIV-1 is enhanced by targeting highly networked epitopes in complex with human-leukocyte-antigen-class-I (HLA-I). However, the extent to which the presenting HLA allele contributes to this process is unknown. Here we examine the CTL response to QW9, a highly networked epitope presented by the disease-protective HLA-B57 and disease-neutral HLA-B53. Despite robust targeting of QW9 in persons expressing either allele, T cell receptor (TCR) cross-recognition of the naturally occurring variant QW9_S3T is consistently reduced when presented by HLA-B53 but not by HLA-B57. Crystal structures show substantial conformational changes from QW9-HLA to QW9_S3T-HLA by both alleles. The TCR-QW9-B53 ternary complex structure manifests how the QW9-B53 can elicit effective CTLs and suggests sterically hindered cross-recognition by QW9_S3T-B53. We observe populations of cross-reactive TCRs for B57, but not B53 and also find greater peptide-HLA stability for B57 in comparison to B53. These data demonstrate differential impacts of HLAs on TCR cross-recognition and antigen presentation of a naturally arising variant, with important implications for vaccine design.

Indexed as

HIV InfectionsEpitopes, T-LymphocyteHLA-B AntigensHumansPeptidesReceptors, Antigen, T-CellT-Lymphocytes, CytotoxicEpitopes, T-LymphocyteHLA-B AntigensPeptidesReceptors, Antigen, T-Cell

Identifiers

PMID37217466
PMCPMC10202051
OpenAlexW4377292150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.